Working until the end of the year, Federal Circuit addresses a Law School Exam Type Case The Federal Circuit affirmed a Southern District of Indiana decision that generic drug makers IVAX Pharmaceuticals, Inc, Dr. Reddy’s Labratories, Ltd. (DRL) and Teva Pharmaceuticals USA, Inc. infringed Eli Lilly and Company’s (Lilly) U.S. Patent no. 5,229,382. The ‘382 Patent claims chemical compound olanzapine and the use of the compound to treat schizophrenia. The infringers […] Continue Reading →
Speak Now or Forever Hold Your Peace – Failure to Raise Verdict Inconsistency Defeats Appeal In L&W, Inc. v. Shertech, Inc. and Steven W. Sheridan (“Shertech”), the Court affirmed in part the decision of the US District Court for the Eastern District of Michigan holding claim 7 valid and claim 10 invalid of Shertech’s ‘264 patent, and affirming the portion of the judgment holding that the ‘264 patent was not […] Continue Reading →
Enablement standard for prior art less stringent than enablement standard for patents The Federal Circuit, in Impax Laboratories, Inc. v. Aventis Pharmaceuticals Inc., discussed the requirements for a prior art reference to be enabled, and thus anticipate a patent. Aventis is the owner of U.S. Patent No. 5,527,814, covering the use of the compound riluzole to treat ALS, commonly known as Lou Gehrig’s disease. Impax wanted to […] Continue Reading →